BRAF V600K Inhibitors
1 drugsAbout BRAF V600K
BRAF V600K is a mutated form of the BRAF protein, a kinase in the MAPK signaling pathway that regulates cell growth and proliferation. The V600K mutation results in constitutive activation of the BRAF kinase, leading to uncontrolled cell growth and tumor development.
BRAF V600K is a target in oncology, though there is currently no genetic evidence data available specifically linking the V600K mutation to diseases in this dataset. The clinical significance of BRAF V600K is highlighted by the existence of targeted therapies.
Tafinlar (dabrafenib) is the only FDA-approved drug targeting BRAF V600K, developed by Novartis for 4 oncology indications. It is a small molecule, and was first approved in 2013.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Advanced Lymphoma with only 2 trials.
- phase1 represents biological uncertainty with 55% completion.
Top BRAF V600K Drugs
Novartis is the only company with an approved drug targeting BRAF V600K.
High market concentration suggests high entry barriers or limited commercial opportunity.
BRAF V600K Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets BRAF V600K, using small molecule modality.
Explore alternative modalities like antibodies or PROTACs to differentiate from existing therapies.
BRAF V600K Clinical Trials 91 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 33 | 12 | 13 | 7 | 48% |
| Phase 2 | 47 | 14 | 12 | 21 | 54% |
| Phase 3 | 8 | 4 | 1 | 3 | 80% |
| Phase 4 | 3 | 0 | 0 | 3 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
BRAF V600K Drug Approval Timeline (2013 - 2013)
The first and only drug, Tafinlar, was approved in 2013.
The approval timeline suggests a saturated market, requiring novel approaches for further development.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 84 clinical trials targeting BRAF V600K.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities